ACHN stock news

Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up. Read more
Investors are responding enthusiastically to a key FDA designation for the biotech's leading pipeline candidate. Read more
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more

Achillion: Shifted Gears For Success

04:37pm, Monday, 19'th Aug 2019
Achillion Pharmaceuticals delivered extremely robust outcomes for the Phase 1 study of ACH-5228 and thereby galvanized the shares to trade multiple folds higher Read more
Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter. Read more
Shares have risen by 95% over the past five trading days. I provide a brief overview of the company and a recap of recent events. Management projects 2019 cash Read more
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more
Top Health Care Stocks Top Health Care Stocks JNJ 0 43 JNJ 0 43 PFE 0 74 PFE 0 74 ABT 0 13 ABT 0 13 MRK 0 76 MRK 0 76 AMGN FlatAMGN Flat Most health care giants were lower in Friday s pre bell trade Most health care giants were lower in Friday s pre bell trade Stocks Read more
- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa., May 17, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today reported interim data from a Phase 2 paroxysmal nocturnal hemoglobinuria (PNH) trial assessing the safety and effectiveness of its oral small molecule factor D inhibitor ACH-4471 in combination with intravenous eculizumab at The New Era of Aplastic Anemia and PNH Meeting in Naples, Italy. "Anemia is a persistent problem in the majority of patients with PNH treated with standard and even high doses of eculizumab. These interim data are encouraging and demonstrate that ACH-4471, when used in combination with a C5 inhibitor, such as eculizumab, has the potential to improve anemia, decrease transfusions and lead to improvement in important clinical parameters of hemolysis as well as quality of life measurements for patients with this devastating condition," stated Joseph Truitt, Chief Executive Officer at Achillion. Read more
The clinical-stage biotech didn't have any revenue in the first quarter. But it made progress in several key areas. Read more

Proudly made at

ROCKIT